Pro-Pharmaceuticals, Inc. (PRW) Meeting Scheduled With The FDA; April 11th Meeting To Discuss NDA Submission For Co-administration Of DAVANAT(R) With 5-FU To Treat Cancer Patients
2/23/2007 12:42:45 PM
NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (Amex: PRW), a developer of novel carbohydrate compounds, today announced that a meeting with the U.S. Food & Drug Administration (FDA) is scheduled for April 11th to discuss data and plans for submitting a New Drug Application (NDA), under Section 505(b)(2) for DAVANAT® to be co-administered with 5-Fluorouracil (5-FU) to treat cancer patients. 5-FU is one of the most widely used chemotherapy drugs in the world.
comments powered by